Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

NCT02159989 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

83

Enrollment

NIH

Sponsor class

Conditions

Advanced Malignant Solid Neoplasm
Fibrolamellar Carcinoma
Metastatic Malignant Solid Neoplasm
Ovarian Carcinoma
Pancreatic Neuroendocrine Tumor
Recurrent Malignant Solid Neoplasm
Refractory Malignant Solid Neoplasm
Unresectable Solid Neoplasm

Interventions

DRUG: Sapanisertib
BIOLOGICAL: Ziv-Aflibercept

Sponsor

National Cancer Institute (NCI)